德琪医药塞利尼索15项研究及成果将在2021 ASCO公布

致力于研发和商业化创新肿瘤疗法的领先生物制药公司——德琪医药有限公司(简称“德琪医药”，香港联交所股票代码：6996.HK)今日宣布，同类首款选择性核输出抑制剂——塞利尼索(selinexor)15项研究及成果将在2021年美国临床肿瘤学大会(ASCO)年会上公布。此届 ASCO 会议于6月4日至6月8日在线上召开。

线上摘要

Effects of weekly selinexor, bortezomib, dexamethasone (XVd) versus standard twice weekly bortezomib and dexamethasone (Vd) on RAS-mutated previously treated multiple myeloma (MM).

摘要编号：8027

Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone(Vd) in patients with previously treated multiple myeloma.

摘要编号：8024

Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study.

摘要编号：8019

Updated overall survival of eltanexor for the treatment of patients with hypomethylating agent refractory myelodysplastic syndrome.

摘要编号：e19037

Results of the phase 2 MARCH Study: Oral ATG-010 (Selinexor) plus low dosedexamethasone in Chinese patients with relapsed/refractory multiple myeloma (RRMM) previously treated with an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI).

摘要编号：e20002

Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM).

摘要编号：8018

SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer.

摘要编号：TPS5610

Open-label phase 1 study evaluating the tolerability and anti-tumor activity of selinexor and pembrolizumab in colorectal cancer.

摘要编号：e15579

A phase 1/2 study of selinexor in combination with standard of care therapy for newly diagnosed or recurrent glioblastoma.

摘要编号：TPS2071

A phase Ib/II study of selinexor in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST): SeliGIST/GEIS-41 trial.

摘要编号：11534

Selinexor in combination with weekly paclitaxel in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multiarm phase 1b study.

摘要编号：5565

Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.

摘要编号：8038

A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand.

摘要编号：TPS8055

Molecular predictors of response to selinexor in advanced unresectable de-differentiated liposarcoma (DDLS).

摘要编号：11509

Selinexor containing regimens in patients with multiple myeloma (MM) previously treated with anti-CD38 monoclonal antibodies (αCD38 mAbs).

摘要编号：e20020

关于德琪医药

德琪医药有限公司(简称“德琪医药”，香港联交所股票代码：6996.HK)是一家以研发为驱动的生物制药领先企业，致力于为亚太乃至全球患者提供最领先的疗法，治疗肿瘤及其他危及生命的疾病。自2017年正式运营以来，德琪医药通过合作引进和自主研发，建立了一条从临床前到临床阶段不断延展的丰富产品管线。目前，德琪医药已在多个亚太市场获得15个临床批件(IND)，并递交了5个新药上市申请(NDA)。德琪医药将以“医者无疆，创新永续”为愿景，专注于同类首款和同类最优疗法的早期研发、临床研究、药物生产及商业化，解决亟待满足的临床需求。

(新媒体责编：syhz0808)